Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
Journal Information
Full Title: Int J Cancer
Abbreviation: Int J Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"CONFLICT OF INTEREST F. Bertolini reports research support from Menarini, Gilead, Pierre Fabre and Arqule. N. Colombo reports personal fees from AstraZeneca, Novartis, Clovis Oncology, MSD, GSK, Roche, Pfizer, Immunogen, Mersana, Eisai, OncXerna and Nuvation Bio. All other authors report no conflict of interest."
Funding Disclosure
Evidence found in paper:
"We thank AIRC (Associazione Italiana Ricerca sul Cancro) and the Italian Ministry of Health for support of our research. We thank San Francisco Edit for editing of our article. Open access funding enabled and organized by Projekt DEAL."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025